From hypertension to heart failure - Are there better primary prevention strategies?

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 2, 2006, Pages 64-73

  Meredith, Peter A ^a   Östergren, Jan ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AT1 receptor blockers; Atrial fibrillation; Heart failure; Hypertension; New onset diabetes; Renin angiotensin aldosterone system

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IRBESARTAN; LOSARTAN; PERINDOPRIL; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; INCIDENCE; META ANALYSIS; MORBIDITY; MORTALITY; OBESITY; PATIENT COMPLIANCE; POLYPHARMACY; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; QUALITY OF LIFE; RECURRENCE RISK; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SMOKING; STROKE; SYSTEMATIC REVIEW;

ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RISK FACTORS;

EID: 33748696800     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.012     Document Type: Review

References (64)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76.
2. Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European cardiovascular disease statistics. British Heart Foundation: London 2005. Available at http://www.heartstats.org/uploads/ documents%5CPDF.pdf
3. Thom T, Haase N, Rosamond W et al. Heart Disease and Stroke Statistics - 2006 Update: A report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation available at http://www.circulationaha.org
4. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Heart Study. N Engl J Med 1971;285:1441-6.
5. Eriksson H, Svardsudd K, Larsson B et al. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J 1989;10:647-56.
6. Yusuf S, Abbott RA. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989;13(suppl 1):I-74-I-79.
7. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. Am J Coll Cardiol 1993; 32(suppl A): 6A-13A.
8. Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime Risk for Developing Congestive Heart Failure: the Framingham Heart Study. Circulation 2002;106:3068-72.
9. Levy D, Larson MG, Martin G, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
10. Wolf-Maier K. Cooper RS. Banegas JR etal. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289(18):2363-9.
11. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.
12. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med 1996; 156(16):1789-96.
13. Himmelman A. Hypertension: an important precursor of heart failure. Blood Pressure 1999;8:253-60.
14. Croft JB, Giles WH, Pollard RA et al. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999; 159:505-10.
15. Levy D, Garrison RJ, Savage DD etal. Left ventricular mass as incidence of coronary heart disease in an elderly cohort: the Framingham study. Ann Intern Med 1989;110:101-07.
16. Kannel WB, Wolf PA, Garrison RJ (eds). Some risk factors related to the annual incidence of cardiovascular disease and death in pooled, repeated biennial measurements: Framingham Heart Study, 30-year follow-up. Bethesda, MD: National Institutes of Health; 1987:section 34. Publication NIH 87-2703.
17. Weber KT, Brilla CG, Campbell SE, Zhou G, Matsubara L, Guarda F. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press 1992;1:75-85.
18. Lawes CM, Rodgers A, Bennett DA et al. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003;21(4):707-16.
19. Lewington S. Clarke R. Qizilbash N. Peto R. Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-13.
20. Nolan SE, Mannisi JA, Bush DE, Healy B, Weismann HF. Increased afterload aggravates infarct expansion after acute myocardial infarction. J Am Coll Cardiol 1988;12:1318-25.
21. Nishikimi T, Yamagashi H, Takeuchi K, Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 1995;29:856-61.
22. Richards AM, Nichols G, Troughton RW et al. Antecedent hypertension and heart failure after myocardial infarction. JACC 2002; 39(7):1182-8.
23. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693):827-38.
24. Kostis JB, Davis BR, Cutler J et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997;278(3):212-16.
25. Moser M, Herbert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. JACC 1996;27(5):1214-18.
26. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens 1997; 11: 213-20.
27. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001;38:827-32.
28. Meissner I, Whisnant JP, Sheps SG et al. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension 1999;34:466-71.
29. Weinehall L, Öhgren B, Persson M et al. High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. J Hypertens 2002;20(10):2081-8.
30. Conlin PR, Gerth WC, Fox J, Roehm JB. Boccuzzi SJ. Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clinical Therapeutics 2001;23(12):1999-2010.
31. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75.
32. Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003;16:895-9.
33. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
34. Cruickshank J, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy of different types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.
35. Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment Of Mild Hypertension Study (TOMHS). Circulation 1995;91:698-706.
36. Klingbeil AU, Schneider M, Marrus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment of left ventricular mass in essential hypertension. Am J Med 2003;115:41-6.
37. Malmqvist K, Kahan T, Edner M et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-76.
38. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet 2002;359:995-1003.
39. Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalaprit on left ventricular hypertrophy in patients with essential hypertension in treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002;20(11):2293-300.
40. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
41. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
42. Whelton PK. Epidemiology of hypertension. Lancet 1994;344:101-06.
43. Wilhelmsen L, Rosengren A, Eflksson H, Lappas G. Heart failure in the general population of men - morbidity, risk factors and prognosis. J Intern Med 2001;249:253-61.
44. Pedersen OD, Bagger H, Kober L, Torp-Pederson C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80.
45. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926-31.
46. Madrid AH, Bueno MG, Rebollo JMG et al. Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A Prospective and Randomized Study. Circulation 2002;106:331-6.
47. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. JACC 2005;45(5):712-19.
48. Wachtell K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. JACC 2005;45(5):705-11.
49. Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the CHARM Program. Am Heart J 2006;152:86-92.
50. Bell SH. Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26(8):2433-41.
51. Amato L, Paolisso G, Cacciatore F et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly: the Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 1997;23:213-18.
52. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10.
53. Abuissa H, Jones PG, Marso SP, O'Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. JACC 2005;46(5):821-6.
54. Yusuf S, Ostergren JB, Gerstein HC et al. on behalf of the Candesartan in Heart Failure - Assessment of reduction in mortality and morbidity program (CHARM) Investigators. Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients with Heart Failure. Circulation 2005;112:48-53.
55. Carr AA, Kowey PR, Devereux RB et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE Studies. Am J Cardiol 2005;96:1530-6.
56. BPTLLC. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed over-views of randomised trials. Lancet 2003;362:1527-35.
57. Julius S, Kjeldsen SE, Weber M et al. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
58. Dahlof B, Sever PS, Poulter NR et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavia Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
59. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study. ELITE II. Lancet 2000; 355(9215):1582-7.
60. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
61. Granger CB, McMurray J, Yusuf S et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet 2003;362:767-71.
62. McMurray J, Ostergren J, Swedberg K et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet 2003;362:772-6.
63. Yusuf S, Pfeffer M, Swedberg K et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and left ventricular ejection fraction above 40%: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
64. Pfeffer M, Swedberg K, Granger CB et al. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall Programme. Lancet 2003;362:759-66.